NASDAQ · Biotechnology · USD
BriaCell Therapeutics Corp. (BCTX) Stock Analysis
BriaCell Therapeutics Corp. (BCTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 22, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
BCTX Key Statistics
As of Oct 22, 2026Trading
- Open
- $3.64
- Previous Close
- $3.60
- Day's Range
- 3.40–3.67
- 52-Week Range
- 2.60–13.90
- Volume
- 61.70K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.51
Valuation
- Market Cap
- $29.67M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.92
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$4.79M
- Shares Outstanding
- 8.70M
- 1-Year Return
- −71.70%
Dividend and dates
- Avg Volume
- 265.26K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 22, 2026, BCTX closed at $3.41, −71.70% over 1 year.
BriaCell Therapeutics Corp. (BCTX) has a market capitalization of $29.67M.
In fiscal 2024, BCTX reported revenue of $0.00.
BCTX Stock Return by Calendar Year
BriaCell Therapeutics Corp. (BCTX) 10-year return: what $10,000 became
- 1 year
- $10,000 $2,830
- −71.70%
- 5 years
- $10,000 $461
- −95.39%
- 10 years
- $10,000 $71
- −99.29%
If you had invested $10,000 in BriaCell Therapeutics Corp. (BCTX) 10 years ago, at the close on October 21, 2016, it would have been worth $71 at the close on October 22, 2026: −99.29% in total, −39.03% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −52.04% |
| 2025 | +26.96% |
| 2024 | −90.43% |
| 2023 | +33.87% |
| 2022 | −47.22% |
| 2021 | +98.56% |
| 2020 | −53.67% |
| 2019 | −40.00% |
| 2018 | −50.00% |
| 2017 | −33.33% |
| 2016 (partial year) | −16.67% |
As of October 22, 2026.
BCTX Revenue and Earnings by Fiscal Year
FY ends July| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2024 | $0.00 | −$4.79M | — |
| 2023 | $0.00 | −$20.30M | — |
| 2022 | $0.00 | −$26.84M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2024 | $0.00 | — | −$33.33M | −$4.79M | — |
| 2023 | $0.00 | — | −$23.27M | −$20.30M | — |
| 2022 | $0.00 | — | −$15.29M | −$26.84M | — |
Annual figures as reported, in the company's reporting currency. As of July 31, 2024.
Recent News
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
YahooData Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
YahooBriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
YahooMemorial Sloan Kettering Cancer Center Joins BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer
BenzingaBriaCell Therapeutics Advances Bria-MEL+ Whole Cell Melanoma Immunotherapy Vaccine Candidate Toward Clinical Development With Key Genetic Engineering Milestone
BenzingaBriaCell Therapeutics Receives FDA Clearance To Proceed With Clinical Evaluation Of Bria-PROS+, Its Next-Gen Personalized Off-The-Shelf Immunotherapy For Prostate Cancer
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$135.64B
REGNRegeneron Pharmaceuticals, Inc.
$84.33B
MRNAModerna, Inc.
$80.90B
ARGXargenx SE
$55.07B
ONCBeOne Medicines AG
$43.49B
RVMDRevolution Medicines, Inc.
$40.23B
Popular Healthcare Stocks
Eli Lilly and Company
$1.17T
JNJJohnson & Johnson
$644.91B
ABBVAbbVie Inc.
$503.96B
UNHUnitedHealth Group Incorporated
$381.46B
MRKMerck & Co., Inc.
$363.27B